Goals · Specialty & Clinical
Mitochondrial dysfunction, HPA exhaustion, and post-viral fatigue syndromes.
Compounds linked to this goal in the catalogue, ordered by role — primary, then support, then optional. Roles follow peptide-db's per-use effectiveness rating (most effective → primary, effective → support, moderate or thinner → optional); a compound that reaches the goal through a curated stack or a condition page says so. Click any card for the full mechanism, dosing, and evidence.
Synthetic Pineal Tetrapeptide | Telomerase Activator
Half-life: Not established (short peptide)
Essential Cellular Coenzyme & Anti-Aging Therapy
Half-life: 1-4 hours (intracellular)
Mitochondrial-Derived Peptide | Metabolic Regulator
Half-life: ~30 minutes
Support — Curated stack: Cellular Energy (NAD+)
Enhanced Nootropic Peptide | Cognitive Enhancement & Neuroprotection
Half-life: 2-10 hours
Support — Researched for Brain Fog
Synthetic Thymic Hormone | Immune System Modulator
Half-life: ~2 hours
Optional — Researched for Chronic Fatigue Syndrome (ME/CFS)
No SARMs tagged for this goal yet.
Eugeroic | Wakefulness & Cognitive Enhancement
Half-life: ~12-15 hours
Mucolytic | Glutathione Precursor | FDA-Approved Drug
Half-life: ~6 hours (oral); plasma cysteine elevation persists ~12 hours
Support — Curated stack: Wakefulness & Focus
Opioid Antagonist | Low-Dose Anti-Inflammatory & Immune Modulation
Half-life: ~4 hours
Support — Fibromyalgia · effective